Skip to main content
Premium Trial:

Request an Annual Quote

Iconix to Perform Chemogenomic Profiling for Neurocrine

NEW YORK, July 12 (GenomeWeb News) - Iconix Pharmaceuticals will provide Neurocrine Biosciences with chemogenomic analyses on candidate compounds in Neurocrine drug-discovery programs, Iconix said today.


As part of the agreement, Iconix's DrugMatrix technology will be used to provide a gene expression-based chemogenomic work-up on a minimum of 12 Neurocrine compounds.


Iconix will then provide summary analyses to Neurocrine that will include analysis of on- and off-target effects including toxicity as revealed by gene-expression profiles, as well as the impact of the gene-expression changes on critical biological pathways and Iconix's DrugSignatures biomarker information, Iconix said.


Financial terms of the agreement were not disclosed.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.